Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 2 (5), 424-426
- https://doi.org/10.7150/thno.4428
Abstract
This theme issue presents current achievements in the development of radioactive agents, pre-clinical and clinical molecular imaging, and radiotherapy in the context of theranostics in the field of oncology.Keywords
This publication has 9 references indexed in Scilit:
- Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of CancerTheranostics, 2012
- Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)Theranostics, 2012
- How Does the Patient Benefit from Clinical PET?Theranostics, 2012
- Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 PentetreotideTheranostics, 2012
- THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka ExperienceTheranostics, 2012
- Imaging Key Biomarkers of Tumor AngiogenesisTheranostics, 2012
- Imaging of Adrenal Masses with Emphasis on Adrenocortical TumorsTheranostics, 2012
- Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine CarcinomaTheranostics, 2012
- Pretargeted Molecular Imaging and RadioimmunotherapyTheranostics, 2012